BAM
CNST

Bellevue Asset Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Bellevue Asset Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-43
Closed -$1K – 630
2020
Q2 		$1K Buy
+43
New +$1.55K ﹤0.01% 608

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMV
Venrock Management V Palo Alto, California $719M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bellevue Asset Management's CNST Position: Q3 2020 in Review

Bellevue Asset Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2020, closing a stake of 43 shares — an estimated $1K sold.

Bellevue Asset Management first reported a position in CNST in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 119 funds tracked by Wall St. Rank hold CNST as of Q3 2020.

  • Bellevue Asset Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Bellevue Asset Management sold 43 Constellation Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1K.
  • Bellevue Asset Management first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Bellevue Asset Management's Constellation Pharmaceuticals, Inc. position peaked at $1K in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2020.

Based on Bellevue Asset Management's 13F filing for Q3 2020, filed 12 Nov 2020.